Global AI-Enabled Drug Discovery and Clinical Trials Market

Analysis and Forecast, 2019-2030

Published Year: 2020
SKU: BH00818SA

5000

Online Access for One Person. Permission to Print

A quick peek into the report

Report Description

The purpose of this study is to gain a holistic view of the global AI-enabled drug discovery and clinical trials market in terms o

Market Report Coverage - Global AI-Enabled Drug Discovery and Clinical Trials Market

Base Year

2018

Market Size by 2018

$250.0 Million

 

Forecast Period

 

2019-2029

Value Estimation by 2029

 $4238.7 Million

CAGR During Forecast Period

24.88%

Number of Tables

 

Market Segmentation

• Component – Solutions and Services

• Application – Data Aggregation and Analysis, Clinical Trials, Drug Design, Drug Characterization, and Biomarker Research

• Therapeutic Applications – Oncology, Cardiovascular Diseases, Nervous System Diseases, Respiratory Disorder, Metabolic Diseases, Immunologic Diseases, Infectious Diseases, and others

• End-User – Biopharmaceutical Industry, Contract Research Organizations (CROs), and Academic Institutes and Research Centers

Regional Segmentation

• North America – U.S. and Canada

• Europe - U.K., Germany, France, Italy, Spain, and Rest-of-Europe

• Asia-Pacific – China, India, Australia, South Korea, Japan, and Rest-of-Asia-Pacific

• Rest-of-the-World

Key Companies Profiled

Some of the major key players in the global AI-enabled drug discovery and clinical trials market include Accutar Biotechnology Inc., AiCure, LLC, Ardigen, Atomwise, Inc., Benevolent AI, Berg, LLC, Berkeley Lights, Inc., BioAge Labs, Inc., Biovista, Inc., C4X Discovery Holdings Plc, Clinithink Ltd, Cloud Pharmaceuticals, Inc., Cyclica Inc., CytoReason, Concerto HealthAI, Symphony Innovation, LLC, Deep Genomics Inc., DeepThink Health Inc., Envisagenics Inc., and Exscientia Ltd., among others.

Market Segmentation

Market Outlook by Component

On the basis of the overall market share, the solutions segment is anticipated to hold the majority share during the forecast period 2019-2030. The rising cost of the drug discovery and development process has propelled the development of AI solutions. The aim of using these solutions is to improve the time efficiency and cost containment of the drug discovery and development process. The solutions available in the market can be further divided on the basis of their usage area, for instance, aggregation and synthesis of information, generating drug discovery, drug designing, and validation and optimization of drug candidates, among others.

Market Segmentation by Application

The data aggregation and analysis segment is estimated to account for the largest market share, with an overall market holding of 38.13% by 2030. The large share observed can be attributed to the fact that the majority of companies in the market are providing solutions and services for data analysis. Furthermore, the biomarker research segment also witnesses high growth and is expected to occupy 11.62% of the global market revenue by 2030.

Market Segmentation by Therapeutic Applications

Among all therapeutic areas, the oncology segment is expected to account for the largest market share of 33.15% by 2030. Artificial Intelligence (AI) usage in major therapeutic areas includes oncology, cardiovascular diseases, nervous system diseases, respiratory disorder, metabolic diseases, immunologic diseases, and infectious diseases.

Market Segmentation by End-User

On the basis of end-users, the biopharmaceutical industry is expected to dominate the global AI-enabled drug discovery and clinical trials market, while covering an overall market share of 63.53% by 2030. The market has evolved dramatically with increasing drug development expenditure and growing synergistic activities from biopharmaceutical companies, CROs, and academic and research institutions.

Market Segmentation by Region

Due to the growing need to develop novel treatment options for rare diseases, rising biopharmaceutical R&D expenditure, and a rising number of clinical trials in the region, the North American region is expected to dominate the global market in the coming decade. Additionally, the Asia-Pacific region has observed the highest CAGR of 25.59% during the forecast period 2019-2030.

Key Questions Answered in this Report:

How can AI integration in drug discovery and clinical trials decrease drug development expenditure?

•    How can AI integration in drug discovery and clinical trials decrease drug development expenditure? 
•    How are pharmaceutical/biopharmaceutical companies assisting in market development?
•    How can regulatory bodies such as FDA accelerate the AI adoption within the drug discovery and development process?
•    What is the present status of AI adoption in the drug discovery and development processes globally?
•    Which companies are expected to emerge as the key players of the market?
•    How are the companies operating in the market generating revenue?
•    What are the key regulatory implications in developed and developing regions for AI-enabled drug discovery and clinical trials market?
•    How can the companies expand in non-English speaking regions?
•    Which therapeutic area (such as oncology and neurology) has the highest AI adoption rate in clinical trials?
•    Which region is anticipated to serve as an emerging market for drug discovery and clinical trial, respectively?
•    What is the state of AI adoption in the Middle East and Latin America?
•    What are the different methodologies followed by the companies in the market for drug development?

Market Overview

The Global AI-Enabled Drug Discovery and Clinical Trials Market Report by BIS Research projects the market to grow at a significan

Market Overview and Estimation

In the last two decades, the consistent data generation in the healthcare industry has propelled the need for improved technology within the system. According to the NEJM Catalyst (part of NEJM Group, a division of Massachusetts Medical Society), almost 30% of the global data is generated by the healthcare sector. Furthermore, a single patient generates 80 megabytes of data annually.

One of the key technologies for medical research advancement is artificial intelligence (AI), which encompasses various technologies such as machine learning (ML), deep learning, supervised learning, and recursive learning. In the field of medical research, specifically for drug discovery and clinical trials, AI can improve several processes such as data collection and analysis, generation of virtual 3D models depicting drug and ligand binding interaction, designing of clinical studies, optimization of clinical trials, and real-world evidence analysis.

According to our market analysis, the global AI-enabled drug discovery and clinical trials market accounted for a market revenue of $250 million and is estimated to reach the mark of $4238.7 million by the end of 2030, with a whopping CAGR of 24.88% during 2018-2030. The market growth is expected to be pushed by several factors that include the rising drug development expenditure and rising number of synergistic activities.

Regulatory bodies such as the U.S. Food and Drug Administration (FDA) have yielded guidelines and introduced several initiatives for encouraging the implementation of AI in the drug discovery and development process. For instance, the “Enrichment Strategies for Clinical Trial to Support Approval of Human Drugs and Biological Products” developed by the FDA in 2012 encourages technology usage for improving the quality of clinical trials.

Due to the abundance of untapped opportunities, the future of the global market for AI-enabled drug discovery and clinical trials is bright and booming. The market is witness to multiple expansion opportunities in developing economies such as Latin America and in countries with a high geriatric population, such as Japan and China. Furthermore, the Middle East and Saudi Arabia are investing significantly in the healthcare system and hence, serve as an optimum expansion site for the market.

AI-Enabled Drug Discovery and Clinical Trials Market

 

Growth Drivers

 

• Increasing Drug Development Expenditure

• Facilitation of Polypharmacology
• Growing Number of Synergistic Activities

 

Market Challenges

 

• Lack of Regulations

• Ethical Issues

 

Market Opportunities

 

• Expansion of Business in Developing Economies such as India and Brazil

• Introduction of Solutions in Different Languages

Growth Factors

Increasing Drug Development Expenditure

As the global AI-enabled drug discovery and clinical trials market is still in its nascent stage, the macro healthcare industry factors such as the rising emphasis on patient engagement and surging funding activities are expected to have a significant impact on the market during the forecast period. Additionally, various AI integration methods employed by healthcare giants, such as Novartis AG, GlaxoSmithKline plc, and Eli Lilly and Company, are set to shape the market during the forecast period.

Facilitation of Polypharmacology

Polypharmacology is described as the designing of therapeutic agents that could be used for treating multiple diseases. The usage of AI assists the clinicians in understanding the polypharmacology of the compounds virtually. The clinicians can predict the properties of the compounds and their potential side-effects prior to drug development in laboratories.

 

Growing Number of Synergistic Activities

According to a ‘Health at Glance 2017’ report published by Organization for Economic Cooperation and Development (OECD), almost 60% of the R&D expenses in developed economies (the U.S. and Europe) are borne by the industry. This industry has witnessed 221 partnerships, 96 funding activities, 52 product launch and upgradation, and six mergers and acquisitions during the period 2016-2019. The rising funding activities have stemmed from diverse product portfolios and technology enhancement for the market companies.

Table of Contents

1 Product Definition

   1.1    Inclusion and Exclusion

2 Scope of the Report

         2.1    Scope of the Study
         2.2    Key Questions Answered in the Report

3 Research Methodology

         3.1    Primary Data Sources
         3.2    Secondary Data Sources
         3.3    Market Estimation Model
         3.4    Companies Profiled
         3.5    Assumptions and Limitations

4 Industry Analysis

         4.1    Industry Trends
                  4.1.1    Incorporation Trends
         4.2    Value Analysis
                  4.2.1    Drug Discovery
                  4.2.2    Clinical Trials
         4.3    Regulatory Framework and Government Initiatives
                  4.3.1    Regulatory Framework in North America
                  4.3.2    Regulatory Framework in Europe
                  4.3.3    Government Initiatives
                              4.3.3.1    Government Initiatives in North America
                              4.3.3.2    Government Initiatives in Europe

5 Pipeline Analysis

6 Competitive Landscape

         6.1    Key Developments and Strategies
                  6.1.1    Collaborations and Partnerships
                  6.1.2    Funding
                  6.1.3    Product Launch and Upgradation
                  6.1.4    Mergers and Acquisitions
                  6.1.5    Others
         6.2    Business Model Analysis
                  6.2.1    Subscription
                  6.2.2    Software as a Service and Platform as a Service (SaaS and PaaS)
                  6.2.3    Pay Per Use Model
         6.3    Competitive Benchmarking

7 Market Dynamics

         7.1    Market Drivers
                  7.1.1    Increasing Drug Development Expenditure
                  7.1.2    Facilitation of Polypharmacology
                  7.1.3    Growing Number of Synergistic Activities
         7.2    Market Restraints
                  7.2.1    Lack of Regulations
                  7.2.2    Ethical Issues
         7.3    Market Opportunities
                  7.3.1    Expansion of Business in Developing Economies such as India and Brazil
                  7.3.2    Introduction of Solutions in Different Languages

8 Global AI-enabled Drug Discovery and Clinical Trials Market

         8.1    Assumptions and Limitations
         8.2    Key Findings and Opportunity Assessment
                  8.2.1    Key Findings
                  8.2.2    Opportunity Assessment

9 Global AI-enabled Drug Discovery and Clinical Trials Market (by Component)

         9.1    Overview
         9.2    Solutions
         9.3    Services

10 Global AI-Enabled Drug Discovery and Clinical Trials Market (by Application)

           10.1    Overview
           10.2    Data Aggregation and Analysis
           10.3    Clinical Trials
           10.4    Drug Design
           10.5    Drug Characterization
           10.6    Biomarker Research

11 Global AI-Enabled Drug Discovery and Clinical Trials Market (by Therapeutic Applications)

           11.1    Overview
           11.2    Oncology
           11.3    Cardiovascular Diseases
           11.4    Nervous System Diseases
           11.5    Respiratory Disorder
           11.6    Metabolic Diseases
           11.7    Immunologic Diseases
           11.8    Infectious Diseases
           11.9    Others

12 Global AI-Enabled Drug Discovery and Clinical Trials Market (by End User)

           12.1    Overview
           12.2    Biopharmaceutical Industry
           12.3    Contract Research Organizations (CROs)
           12.4    Academic Institutes and Research Centers

13 Global AI-Enabled Drug Discovery and Clinical Trials Market (by Region)

           13.1    Overview
           13.2    North America
                      13.2.1    U.S.
                      13.2.2    Canada
           13.3    Europe
                      13.3.1    Germany
                      13.3.2    U.K.
                      13.3.3    France
                      13.3.4    Italy
                      13.3.5    Spain
                      13.3.6    Rest-of-Europe
           13.4    Asia-Pacific
                      13.4.1    China
                      13.4.2    Japan
                      13.4.3    South Korea
                      13.4.4    Australia
                      13.4.5    India
                      13.4.6    Rest-of-Asia-Pacific
           13.5    Rest-of-the-World

14 Company Profiles

           14.1    Accutar Biotechnology Inc.
                      14.1.1    Company Overview
                      14.1.2    Role of Accutar Biotechnology Inc. in Global AI-Enabled Drug Discovery and Clinical Trials Market
                      14.1.3    SWOT Analysis
           14.2    AiCure, LLC
                      14.2.1    Company Overview
                      14.2.2    Role of AiCure, LLC in Global AI-Enabled Drug Discovery and Clinical Trials Market
                      14.2.3    SWOT Analysis
           14.3    Ardigen
                      14.3.1    Company Overview
                      14.3.2    Role of Ardigen in Global AI-Enabled Drug Discovery and Clinical Trials Market
                      14.3.3    SWOT Analysis
           14.4    Atomwise, Inc.
                      14.4.1    Company Overview
                      14.4.2    Role of Atomwise, Inc. in Global AI-Enabled Drug Discovery and Clinical Trials Market
                      14.4.3    SWOT Analysis
           14.5    BenevolentAI
                      14.5.1    Company Overview
                      14.5.2    Role of BenevolentAI in the Global AI-Enabled Drug Discovery and Clinical Trials Market
                      14.5.3    SWOT Analysis
           14.6    Berg LLC
                      14.6.1    Company Overview
                      14.6.2    Role of Berg LLC in the Global AI-Enabled Drug Discovery and Clinical Trials Market
                      14.6.3    SWOT Analysis
           14.7    Berkeley Lights, Inc.
                      14.7.1    Company Overview
                      14.7.2    Role of Berkeley Lights, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
                      14.7.3    SWOT Analysis
           14.8    BioAge Labs, Inc.
                      14.8.1    Company Overview
                      14.8.2    Role of BioAge Labs, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
                      14.8.3    SWOT Analysis
           14.9    Biovista Inc.
                      14.9.1    Company Overview
                      14.9.2    Role of Biovista Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
                      14.9.3    SWOT Analysis
          14.10   C4X Discovery Holdings Plc
                      14.10.1    Company Overview
                      14.10.2    Role of C4X Discovery Holdings Plc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
                      14.10.3    Financials
                      14.10.4    Key Insights About the Financial Health of the Company
                      14.10.5    SWOT Analysis
          14.11   Clinithink Ltd
                      14.11.1    Company Overview
                      14.11.2    Role of Clinithink Ltd in the Global AI-Enabled Drug Discovery and Clinical Trials Market
                      14.11.3    SWOT Analysis
          14.12   Cloud Pharmaceuticals, Inc.
                      14.12.1    Company Overview
                      14.12.2    Role of Cloud Pharmaceuticals, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
                      14.12.3    SWOT Analysis
          14.13   Cyclica, Inc.
                      14.13.1    Company Overview
                      14.13.2    Role of Cyclica, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
                      14.13.3    SWOT Analysis
          14.14   CytoReason
                      14.14.1    Company Overview
                      14.14.2    Role of CytoReason in Global AI-Enabled Drug Discovery and Clinical Trials Market
                      14.14.3    SWOT Analysis
          14.15   Symphony Innovation, LLC
                      14.15.1    Company Overview
                      14.15.2    Role of Symphony Innovation, LLC in the Global AI-Enabled Drug Discovery and Clinical Trials Market
                      14.15.3    SWOT Analysis
         Company Snapshots
         14.16   Deep Genomics Inc.
                     14.16.1    Company Overview
                     14.16.2    Role of Deep Genomics Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
          14.17   DeepThink Health Inc.
                      14.17.1    Company Overview
                      14.17.2    Role of DeepThink Health Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
          14.18   Envisagenics, Inc.
                      14.18.1    Company Overview
                      14.18.2    Role of Envisagenics, Inc. in Global AI-Enabled Drug Discovery and Clinical Trials Market
          14.19   Exscientia Limited
                      14.19.1    Company Overview
                      14.19.2    Role of Exscientia Limited in Global AI-Enabled Drug Discovery and Clinical Trials Market
          14.20   e-therapeutics plc
                      14.20.1    Company Overview
                      14.20.2    Role of e-therapeutics plc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
                      14.20.3    Financials
          14.21   GNS Healthcare
                      14.21.1    Company Overview
                      14.21.2    Role of GNS Healthcare in Global AI-Enabled Drug Discovery and Clinical Trials Market
          14.22   Insilico Medicine
                      14.22.1    Company Overview
                      14.22.2    Role of Insilico Medicine in the Global AI-Enabled Drug Discovery and Clinical Trials Market
          14.23   Lantern Pharma Inc.
                      14.23.1    Company Overview
                      14.23.2    Role of Lantern Pharma Inc.  in the Global AI-Enabled Drug Discovery and Clinical Trials Market
          14.24   Medable, Inc.
                      14.24.1    Company Overview
                      14.24.2    Role of Medable, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
          14.25   Mind the Byte
                      14.25.1    Company Overview
                      14.25.2    Role of Mind the Byte in the Global AI-Enabled Drug Discovery and Clinical Trials Market
          14.26   NuMedii, Inc
                      14.26.1    Company Overview
                      14.26.2    Role of NuMedii, Inc. in Global AI-Enabled Drug Discovery and Clinical Trials Market
          14.27   Nuritas, Ltd.
                      14.27.1    Company Overview
                      14.27.2    Role of Nuritas, Ltd. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
          14.28   Owkin, Inc.
                      14.28.1    Company Overview
                      14.28.2    Role of Owkin, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
          14.29   Recursion Pharmaceuticals, Inc.
                      14.29.1    Company Overview
                      14.29.2    Role of Recursion Pharmaceuticals, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
          14.30   Schrödinger, LLC
                      14.30.1    Company Overview
                      14.30.2    Role of Schrödinger, LLC in the Global AI-Enabled Drug Discovery and Clinical Trials Market
          14.31   TARA Biosystems, Inc.
                      14.31.1    Company Overview
                      14.31.2    Role of TARA Biosystems, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
          14.32   twoXAR, Incorporated
                      14.32.1    Company Overview
                      14.32.2    Role of twoXAR, Incorporated in the Global AI-Enabled Drug Discovery and Clinical Trials Market
          14.33   Verge Analytics, Inc.
                      14.33.1    Company Overview
                      14.33.2    Role of Verge Analytics, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
          14.34   Winterlight Labs Inc.
                      14.34.1    Company Overview
                      14.34.2    Role of Winterlight Labs, Inc. in the Global AI-Enabled Drug Discovery and Clinical Trials Market
          14.35   WuXi Nextcode Genomics
                      14.35.1    Company Overview
                      14.35.2    Role of WuXi Nextcode Genomics in Global AI-Enabled Drug Discovery and Clinical Trials Market
          14.36   XtalPi Inc.
                      14.36.1    Company Overview
                      14.36.2    Role of XtalPi Inc. in Global AI-Enabled Drug Discovery and Clinical Trials Market

List of Tables

Table 4.1:    AI Incorporation by Healthcare Companies
Table 4.2:    Regulatory Framework for AI-Enabled Drug Discovery and Clinical Trials Market in North America
Table 4.3:    Regulatory Framework for AI-Enabled Drug Discovery and Clinical Trials Market in Europe
Table 4.4:    Government Initiatives for AI-Enabled Drug Discovery and Clinical Trials Market in North America
Table 4.5:    Government Initiatives for AI-Enabled Drug Discovery and Clinical Trials Market in Europe
Table 5.1:    AI-Enabled Drugs Pipeline
Table 6.1:    Competitive Benchmarking: Global AI-Enabled Drug Discovery and Clinical Trials Market
Table 10.1:    Solution Providers: Drug Characterization
Table 13.1:    Rest-of-the-World: Country-Wise Analysis, 2019-2030

List of Figures

Figure 1:    Global AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 2:    Impact Analysis
Figure 3:    Share of Different Strategies
Figure 4:    Global AI-Enabled Drug Discovery and Clinical Trials Market, by Component 2018 vs. 2030 ($Million)
Figure 5:    Global AI-Enabled Drug Discovery and Clinical Trials Market, by Application,  2018 vs. 2030 ($Million)
Figure 6:    Global AI-Enabled Drug Discovery and Clinical Trials Market, by Therapeutic Application, 2018 vs. 2030 ($Million)
Figure 7:    Global AI-Enabled Drug Discovery and Clinical Trials Market, by End User,  2018 vs. 2030 ($Million)
Figure 8:    Global AI-Enabled Drug Discovery and Clinical Trials Market Snapshot
Figure 2.1:    Global AI-Enabled Drug Discovery and Clinical Trials Market Segmentation
Figure 3.1:    Global AI-Enabled Drug Discovery and Clinical Trials Market Methodology
Figure 3.2:    Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.3:    Top-Down Approach (Segment-Wise Analysis)
Figure 4.1:    Value Analysis: Drug Discovery
Figure 4.2:    Stages of Clinical Trials
Figure 6.1:    Share of Key Developments and Strategies, 2016-2019
Figure 6.2:    Collaborations and Partnerships Share (by Company), 2016-2019
Figure 6.3:    Funding Activity Share (by Company), 2016-2019
Figure 6.4:    Product Launches (by Company), 2016-2019
Figure 6.5:    Mergers and Acquisitions (by Company), 2016-2019
Figure 6.6:    Other Activities (by Share), 2016-2019
Figure 7.1:    Rising Drug Development Expenditure ($Billion), 1970s-2010s
Figure 7.2:    Pharmaceutical vs.  Government R&D Expenditure, 2014
Figure 9.1:    Global AI-Enabled Drug Discovery and Clinical Trials Market (by Component)
Figure 9.2:    AI-Enabled Solutions for Drug Discovery and Clinical Trials: Usage Areas
Figure 9.3:    Global AI-Enabled Drug Discovery and Clinical Trials Market (Solutions), 2018-2030
Figure 9.4:    Global AI-Enabled Drug Discovery and Clinical Trials Market (Services), 2018-2030
Figure 10.1:    Global AI-Enabled Drug Discovery and Clinical Trials Market (by Application)
Figure 10.2:    Global AI-Enabled Drug Discovery and Clinical Trials Market (Data Aggregation and Analysis), 2018-2030
Figure 10.3:    Global AI-Enabled Drug Discovery and Clinical Trials Market (Clinical Trials), 2018-2030
Figure 10.4:    Global AI-Enabled Drug Discovery and Clinical Trials Market (Drug Design), 2018-2030
Figure 10.5:    Global AI-Enabled Drug Discovery and Clinical Trials Market (Drug Characterization), 2018-2030
Figure 10.6:    Global AI-Enabled Drug Discovery and Clinical Trials Market (Biomarker Research), 2018-2030
Figure 11.1:    AI Usage: Therapeutic Sections
Figure 11.2:    AI-Enabled Oncology Clinical Trials (by Country)
Figure 11.3:    Global AI-Enabled Drug Discovery and Clinical Trials Market (Oncology), 2018-2030
Figure 11.4:    AI-Enabled Cardiovascular Diseases Clinical Trials (by Country)
Figure 11.5:    Global AI-Enabled Drug Discovery and Clinical Trials Market (Cardiovascular Diseases), 2018-2030
Figure 11.6:    AI-Enabled Nervous System Diseases Clinical Trials (by Country)
Figure 11.7:    Global AI-Enabled Drug Discovery and Clinical Trials Market (Nervous System Diseases), 2018-2030
Figure 11.8:    AI-Enabled Respiratory Disorders Clinical Trials (by Country)
Figure 11.9:    Global AI-Enabled Drug Discovery and Clinical Trials Market (Respiratory Disorder), 2018-2030
Figure 11.10:    AI-Enabled Metabolic Diseases Clinical Trials (by Country)
Figure 11.11:    Global AI-Enabled Drug Discovery and Clinical Trials Market (Metabolic Diseases), 2018-2030
Figure 11.12:    AI-Enabled Immunologic Diseases Clinical Trials (by Country)
Figure 11.13:    Global AI-Enabled Drug Discovery and Clinical Trials Market (Immunologic Diseases), 2018-2030
Figure 11.14:    Global AI-Enabled Drug Discovery and Clinical Trials Market (Infectious Diseases), 2018-2030
Figure 11.15:    Global AI-Enabled Drug Discovery and Clinical Trials Market (Others), 2018-2030
Figure 12.1:    Global AI-Enabled Drug Discovery and Clinical Trials Market (Biopharmaceutical Industry), 2018-2030
Figure 12.2:    Global AI-Enabled Drug Discovery and Clinical Trials Market (CROs), 2018-2030
Figure 12.3:    Global AI-Enabled Drug Discovery and Clinical Trials Market (Academic Institutes and Research Centers), 2018-2030
Figure 13.1:    Global AI-Enabled Drug Discovery and Clinical Trials Market (by Region)
Figure 13.2:    Global AI-Enabled Drug Discovery and Clinical Trials Market (by Region) 2018 vs. 2030
Figure 13.3:    North America AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.4:    North America: Market Dynamics
Figure 13.5:    North America AI-Enabled Drug Discovery and Clinical Trials Market (by Country) 2018 vs. 2030
Figure 13.6:    U.S. AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.7:    Canada AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.8:    Europe AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.9:    Europe: Market Dynamics
Figure 13.10:    Europe AI-Enabled Drug Discovery and Clinical Trials Market (by Country) 2018-2030
Figure 13.11:    Germany AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.12:    U.K. AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.13:    France AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.14:    Italy AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.15:    Spain AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.16:    Rest-of-Europe AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.17:    Asia-Pacific AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.18:    Asia-Pacific: Market Dynamics
Figure 13.19:    Asia-Pacific AI-Enabled Drug Discovery and Clinical Trials Market (by Country) 2018 vs 2030
Figure 13.20:    China AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.21:    Japan AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.22:    South Korea AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.23:    Australia AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.24:    India AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.25:    Rest-of-Asia-Pacific AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 13.26:    Rest-of-the-World AI-Enabled Drug Discovery and Clinical Trials Market, 2018-2030
Figure 14.1:    Accutar Biotechnology Inc.: Product Offerings
Figure 14.2:    Accutar Biotechnology Inc.: SWOT Analysis
Figure 14.3:    AiCure, LLC: Product Offerings
Figure 14.4:    AiCure, LLC: SWOT Analysis
Figure 14.5:    Ardigen: Product Offerings
Figure 14.6:    Ardigen: SWOT Analysis
Figure 14.7:    Atomwise, Inc.: Product Offerings
Figure 14.8:    Atomwise, Inc.: SWOT Analysis
Figure 14.9:    BenevolentAI: Product Offerings
Figure 14.10:    BenevolentAI.: SWOT Analysis
Figure 14.11:    Berg LLC: Product Offerings
Figure 14.12:    Berg LLC: SWOT Analysis
Figure 14.13:    Berkeley Lights, Inc.: Product Offerings
Figure 14.14:    Berkeley Lights, Inc.: SWOT Analysis
Figure 14.15:    BioAge Labs, Inc.: Product Offerings
Figure 14.16:    BioAge Labs, Inc.: SWOT Analysis
Figure 14.17:    Biovista Inc.: Product Offerings
Figure 14.18:    Biovista Inc.: SWOT Analysis
Figure 14.19:    C4X Discovery Holdings Plc: Product Offerings
Figure 14.20:    C4X Discovery Holdings Plc: Overall Financials (2016-2018)
Figure 14.21:    C4X Discovery Holdings Plc: R&D Expenditure (2016-2018)
Figure 14.22:    C4X Discovery Holdings Plc.: SWOT Analysis
Figure 14.23:    Clinithink Ltd: Product Offerings
Figure 14.24:    Clinithink Ltd: SWOT Analysis
Figure 14.25:    Cloud Pharmaceuticals: Product Offerings
Figure 14.26:    Cloud Pharmaceuticals, Inc.: SWOT Analysis
Figure 14.27:    Cyclica, Inc.: Product Offerings
Figure 14.28:    Cyclica, Inc.: SWOT Analysis
Figure 14.29:    CytoReason.: Product Offerings
Figure 14.30:    CytoReason: SWOT Analysis
Figure 14.31:    Concerto HealthAI: Product Offerings
Figure 14.32:    Concerto HealthAI: SWOT Analysis
Figure 14.33:    e-therapeutics plc: Overall Financials (2016-2018)
Figure 14.34:    e-therapeutics plc: R&D Expenditure (2016-2018)

You may also like

Published Year: 2018

Global Big Data in Healthcare Market: Analysis and Forecast, 2017-2025 (Focus on Components and Services, Applications, Competitive Landscape and Country Analysis)

The global big data in healthcare market was estimated to be worth $14.25 billion in 2017, and...

 
Published Year: 2017

Global Population Health Management Solutions Market : Analysis and Forecast (2017-2025) (Focus on Products (Software & Services), Country Analysis, End Users, Competitive Landscape, Market Share Analysis, and Region Specific Information)

The global population health management solution market can be segmented on the basis of type...

 

Global AI-Enabled Drug Discovery and Clinical Trials Market

Analysis and Forecast, 2019-2030